title: Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer.
abstract: BACKGROUND
  High fasting plasma proneurotensin concentration was associated with the development of breast cancer in the Malmö Diet and Cancer Study (MDCS). Here, we aimed at replicating the initial finding in an independent second cohort.
  
  
  METHODS
  The Malmö Preventive Project (MPP) is a population study and comprised 18,240 subjects when examined in 2002-2006. Of women without history of breast cancer at examination, we included all who developed breast cancer during follow-up (n = 130) until December 31, 2010, and a random sample of women without breast cancer until the end of follow-up (n = 1,439) for baseline plasma proneurotensin assessment (mean age, 70.0 ± 4.4 years). Proneurotensin was measured in fasting plasma samples and was related to the risk of later breast cancer development using multivariate logistic regression.
  
  
  RESULTS
  Proneurotensin [odds ratio (OR) per standard deviation (SD) increment of LN-transformed proneurotensin] was significantly related to incident breast cancer [OR, 2.09; 95% confidence interval (CI), 1.79-2.44; P < 0.001; adjusted for age, body mass index (BMI), smoking, and hormone replacement therapy]. The effect estimate in the MPP was larger than in the discovery cohort (MDCS), with the main difference between the two cohorts being that women of the MPP study were on the average about 10 years older and follow-up time was shorter than that of the MDCS.
  
  
  CONCLUSIONS
  As initially found in the MDCS, fasting plasma proneurotensin was significantly associated with the development of breast cancer in the MPP study as well.
  
  
  CONCLUSIONS
  Measurement of plasma proneurotensin warrants further investigation as a blood-based marker for early breast cancer detection.
authors.affiliation: Department of Clinical Sciences, Lund University, Malmö; Center of Emergency Medicine, Departments of olle.melander@med.lu.se.
authors.forename: Olle
authors.initials: O
authors.lastname: Melander
authors.affiliation: Section of Oncology, Lund University, Lund; Oncology, Skane University Hospital, Lund and Malmö, Sweden;
authors.forename: Mattias
authors.initials: M
authors.lastname: Belting
authors.affiliation: Department of Clinical Sciences, Lund University, Malmö; Surgery and.
authors.forename: Jonas
authors.initials: J
authors.lastname: Manjer
authors.affiliation: Veterans Affairs San Diego Healthcare Systems, San Diego, California;
authors.forename: Alan S
authors.initials: AS
authors.lastname: Maisel
authors.affiliation: Department of Clinical Sciences, Lund University, Malmö; Center of Emergency Medicine, Departments of.
authors.forename: Bo
authors.initials: B
authors.lastname: Hedblad
authors.affiliation: Department of Clinical Sciences, Lund University, Malmö;
authors.forename: Gunnar
authors.initials: G
authors.lastname: Engström
authors.affiliation: Department of Clinical Sciences, Lund University, Malmö; Center of Emergency Medicine, Departments of.
authors.forename: Peter
authors.initials: P
authors.lastname: Nilsson
authors.affiliation: Sphingotec GmbH, Hennigsdorf; and.
authors.forename: Joachim
authors.initials: J
authors.lastname: Struck
authors.affiliation: Sphingotec GmbH, Hennigsdorf; and.
authors.forename: Oliver
authors.initials: O
authors.lastname: Hartmann
authors.affiliation: Sphingotec GmbH, Hennigsdorf; and Waltraut Bergmann Foundation, Hohen Neuendorf, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Bergmann
authors.affiliation: Department of Clinical Sciences, Lund University, Malmö;
authors.forename: Marju
authors.initials: M
authors.lastname: Orho-Melander
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009496:Neurotensin / Q000097:blood*; D016017:Odds Ratio; D011498:Protein Precursors / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D011498:Protein Precursors; C411471:proneurotensin; D009496:Neurotensin